EntreMed to Abandon Two Cancer Drugs: Transfer Designed to Cut Costs, Reflects Move From Proteins to Smaller Molecules (Post, Feb. 5, 2004)

EntreMed Changes Focus, Trims Loss (Post, May 15, 2003)

EntreMed Narrows Loss by Cutting Costs: Rockville Biotech Firm Says It's Set to Fund Operations Into 2004 (Post, March 5, 2003)

EntreMed Co-Founder Holaday to Leave Company (Post, Jan. 30, 2003)

EntreMed, Rival to Announce Funding Deal: $27 Million Agreement for Stock, Drug-Licensing Options to End Rockville Firm's Cash Crunch (Post, Jan. 2, 2003)

Biotech Sector Bleeds Money: Firms Without Active Product Pipelines Running Out of Cash (Post, Dec. 16, 2002)

EntreMed Alters Agreement With Drugmaker to Save Cash (Post, Dec. 13, 2002)

Patent Suit May Add to EntreMed's Cash Woes (Post, Nov. 21, 2002)

EntreMed Reports Third-Quarter Loss: Rockville Firm Seeks Financing to Avoid Running Out of Money by Year-End (Post, Nov. 15, 2002)

EntreMed 3Q Loss Totals $11.8M (Post, Nov. 14, 2002; 10:00 AM)

After Rocketing to Fame, EntreMed Is in Dire Straits: Firm's Struggle Bodes Ill for Local Biotech (Post, Nov. 7, 2002)

EntreMed's CEO to Step Down (Post, Nov. 6, 2002)

EntreMed's No. 2 Quits During Drive to Cut Expenses (Post, Sept. 27, 2002)

EntreMed Lays Off 30 to Cut Expenses: Md. Firm Aims to Trim Costs by 60% (Post, Sept. 20, 2002)

EntreMed to Lay Off 30, Cut Executive Pay (Post, Aug. 8, 2002)

Three Cancer Drugs Found Safe, EntreMed Says (Post, May 22, 2002)

EntreMed Gets Partner To Treat Blindness: Pair to Study Drug's Effect on Retina (Post, Jan. 24, 2002)

Local Stocks Fall On Reports of Weak Economy (Post, Sept. 10, 2001)

EntreMed Cancer Drugs Get 'Orphan' Status (Post, Aug. 16, 2001)